Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Index
-
Market Cap
36.21B
Enterprise Value
40.05B
Income
643.00M
Sales
10.86B
Book/sh
44.67
Cash/sh
3.02
Employees
25942
IPO
Apr 09, 2019
P/E
57.59
Forward P/E
19.06
PEG
1.44
P/S
3.33
P/B
1.68
P/C
24.87
P/FCF
20.81
EV/EBITDA
16.25
EV/Sales
3.69
Quick Ratio
1.30
Current Ratio
2.09
Debt/Eq
0.25
LT Debt/Eq
0.22
Option/Short
Yes / Yes
EPS (ttm)
1.30
EPS next Y
3.94
EPS next Q
0.88
EPS this Y
13.80%
EPS next Y
12.81%
EPS next 5Y
13.19%
EPS past 3/5Y
42.85% -
Sales past 3/5Y
6.06% 8.77%
EPS Y/Y TTM
-39.47%
Sales Y/Y TTM
8.34%
EPS Q/Q
-100.00%
Sales Q/Q
8.74%
Insider Own
0.11%
Insider Trans
0.00%
Inst Own
51.88%
Inst Trans
-1.33%
ROA
2.06%
ROE
2.94%
ROIC
2.45%
Gross Margin
56.85%
Oper. Margin
10.93%
Profit Margin
5.92%
SMA20
7.03%
SMA50
10.63%
SMA200
4.62%
Trades
Shs Outstand
483.40M
Shs Float
481.57M
52W High
87.64 -14.30%
52W Low
61.83 21.47%
Volatility
2.21% 1.84%
ATR (14)
1.65
RSI (14)
66.01
Beta
0.84
Rel Volume
0.01
Avg Volume
1.76M
Volume
644
Perf Week
2.01%
Perf Month
17.16%
Perf Quarter
-0.32%
Perf Half Y
21.10%
Perf YTD
-4.70%
Perf Year
1.54%
Perf 3Y
3.21%
Perf 5Y
-13.93%
Perf 10Y
-
Prev Close
74.94
Price
75.11
Change %
0.22%
Consensus
Buy
Avg. Price Target
$83.44
Implied Upside
+11.1%
Analysts14incl. previous ratings
Rating Distribution7 Buy · 6 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 07, 2026Initiated
BCS logoBBarclays
Equal Weight$70-6.8%
Aug 13, 2026Downgrade
BBNP Paribas Exane
Outperform → Neutral$79+5.2%
Feb 26, 2026Upgrade
WFC logoWWells Fargo
Equal Weight → Overweight$97+29.1%
Jan 30, 2026Initiated
WWilliam Blair
Mkt Perform
Jan 20, 2026Upgrade
DB logoDDeutsche Bank
Hold → Buy
Jan 09, 2026Downgrade
SF logoSStifel
Buy → Hold
Dec 11, 2025Downgrade
BAC logoBBofA Securities
Buy → Underperform$75-0.1%
Aug 21, 2025Downgrade
JPM logoJJP Morgan
Overweight → Neutral
May 20, 2025Downgrade
DB logoDDeutsche Bank
Buy → Hold
May 14, 2025Reiterated
BBTIG Research
Buy$102 → $99+31.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duplan SergioOfficerFeb 26 '26Proposed Sale86.5415,0001,298,128Feb 26 03:55 PM
Attias LaurentOfficerFeb 26 '26Proposed Sale86.912,412209,634Feb 26 11:22 AM
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the Surgical and Vision Care segments. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner in 1945 and is headquartered in Geneva, Switzerland.
CEO & DirectorMr. David J. Endicott
Senior VP & CFOMr. Timothy C. Stonesifer
Senior VP & COOMr. Ian Bell
Chief Accounting OfficerMargaret Buckley
SVP of Global Research & Development and Chief Scientific OfficerDr. Franck Leveiller Ph.D.